Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus ENTADFI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus ENTADFI.
ATMEKSI vs ENTADFI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Combination of a 5α-reductase inhibitor (finasteride) and a phosphodiesterase 5 inhibitor (tadalafil). Finasteride inhibits type II 5α-reductase, preventing conversion of testosterone to dihydrotestosterone, reducing prostate growth. Tadalafil inhibits PDE5, increasing cGMP in smooth muscle, causing relaxation of the prostate and bladder neck.
1.5 mg/kg IV every 4 weeks
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Finasteride: terminal half-life ~6-8 hours (range 4-12 h) in young adults, 8 hours in elderly. Tadalafil: terminal half-life ~17.5 hours (range 11-28 h), supporting once-daily dosing.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
ENTADFI (finasteride 5 mg and tadalafil 5 mg) is a fixed-dose combination. Finasteride is excreted 57% in feces (as metabolites) and 39% in urine (<1% as unchanged). Tadalafil is excreted primarily as metabolites, with 61% in feces and 36% in urine; <0.001% of dose is excreted unchanged in urine.
Category C
Category C
PDE5 Inhibitor
5-Alpha Reductase Inhibitor and PDE5 Inhibitor